Equities Analysts Issue Forecasts for TENX FY2024 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities researchers at Roth Capital cut their FY2024 earnings per share (EPS) estimates for Tenax Therapeutics in a report released on Wednesday, March 5th. Roth Capital analyst J. Aschoff now forecasts that the specialty pharmaceutical company will post earnings of ($1.20) per share for the year, down from their prior forecast of ($1.16). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.80) EPS and FY2029 earnings at $3.73 EPS.

A number of other brokerages have also recently issued reports on TENX. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday. Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Tenax Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Stock Performance

Shares of NASDAQ:TENX opened at $6.19 on Monday. Tenax Therapeutics has a 12-month low of $2.77 and a 12-month high of $7.89. The business has a 50 day moving average of $6.44 and a 200-day moving average of $5.21.

Institutional Investors Weigh In On Tenax Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vestal Point Capital LP acquired a new stake in shares of Tenax Therapeutics in the third quarter valued at approximately $288,000. Sphera Funds Management LTD. acquired a new position in Tenax Therapeutics during the third quarter valued at approximately $101,000. Stonepine Capital Management LLC acquired a new position in Tenax Therapeutics during the third quarter valued at approximately $173,000. Two Sigma Investments LP acquired a new position in Tenax Therapeutics during the fourth quarter valued at approximately $84,000. Finally, Millennium Management LLC acquired a new position in Tenax Therapeutics during the fourth quarter valued at approximately $166,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.